
NATURE . COM {
}
Title:
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial | Nature Medicine
Description:
Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4–7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier: NCT02662309 ). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21–41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Education
- Science
- Health & Fitness
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌆 Monumental Traffic: 20M - 50M visitors per month
Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$536,300 per month
Our calculations suggest that Nature.com earns between $357,503 and $983,134 monthly online from display advertisements.
Keywords {🔍}
article, cancer, nature, google, scholar, data, patients, cas, urothelial, neoadjuvant, oncology, research, analysis, response, carcinoma, hospital, clinical, study, access, bladder, biomarkers, baseline, tumor, med, medical, medicine, atezolizumab, trial, department, fundinghonoraria, content, metastatic, phase, cells, treatment, chemotherapy, clin, university, extended, samples, information, change, published, biomarker, powles, muscleinvasive, immunotherapy, advanced, nat, immune,
Topics {✒️}
nature portfolio journals permissions reprints nature portfolio privacy policy advertising muscle-invasive bladder cancer muscle-invasive urothelial cancer social media transforming growth factor-β protocol development open-label nature+ nature 554 nature pieter-jan van dam research funding/honoraria european genome-phenome archive alejo rodriguez-vida pd-1/pd-l1 blockade albert font pous cisplatin-based neoadjuvant chemotherapy accession number ega-box-1336 universidad de sevilla pd-1/pd-l1 immunotherapy high-risk resectable melanoma refractory solid tumors platinum-treated locally advanced permissions springerlink instant access barts cancer institute netherlands cancer institute santiago de compostela van der heijden extended data fig advanced urothelial cancers urbano anido herranz maria jose mendez neoadjuvant pd-1 blockade pd-l1 blockade data monitoring committee author correspondence fibroblast activation protein hospital del mar resting memory cells operable urothelial carcinoma gene expression signatures metastatic urothelial carcinoma resectable lung cancer privacy ligand 1 pd-l1
Schema {🗺️}
WebPage:
mainEntity:
headline:Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
description:Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4â7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier:
NCT02662309
). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21â41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
datePublished:2019-11-04T00:00:00Z
dateModified:2023-03-21T00:00:00Z
pageStart:1706
pageEnd:1714
sameAs:https://doi.org/10.1038/s41591-019-0628-7
keywords:
Bladder cancer
Predictive markers
Biomedicine
general
Cancer Research
Metabolic Diseases
Infectious Diseases
Molecular Medicine
Neurosciences
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig3_HTML.png
isPartOf:
name:Nature Medicine
issn:
1546-170X
1078-8956
volumeNumber:25
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Thomas Powles
url:http://orcid.org/0000-0001-7760-4724
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Mark Kockx
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Alejo Rodriguez-Vida
affiliation:
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Ignacio Duran
affiliation:
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
type:Organization
type:Person
name:Simon J. Crabb
url:http://orcid.org/0000-0003-3521-9064
affiliation:
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
type:Organization
type:Person
name:Michiel S. Van Der Heijden
affiliation:
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
type:Organization
type:Person
name:Bernadett Szabados
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Albert Font Pous
affiliation:
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
type:Organization
type:Person
name:Gwenaelle Gravis
affiliation:
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Urbano Anido Herranz
url:http://orcid.org/0000-0003-0376-5642
affiliation:
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
type:Organization
type:Person
name:Andrew Protheroe
url:http://orcid.org/0000-0001-9413-0575
affiliation:
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
type:Organization
type:Person
name:Alain Ravaud
affiliation:
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
type:Organization
type:Person
name:Denis Maillet
affiliation:
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
type:Organization
type:Person
name:Maria Jose Mendez
url:http://orcid.org/0000-0002-7460-1859
affiliation:
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
type:Organization
type:Person
name:Cristina Suarez
affiliation:
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Mark Linch
affiliation:
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
type:Organization
type:Person
name:Aaron Prendergast
url:http://orcid.org/0000-0002-9668-6689
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Pieter-Jan van Dam
url:http://orcid.org/0000-0001-9074-8271
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Diana Stanoeva
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sofie Daelemans
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sanjeev Mariathasan
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Joy S. Tea
url:http://orcid.org/0000-0002-3395-149X
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Kelly Mousa
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Romain Banchereau
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Daniel Castellano
affiliation:
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
description:Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4â7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier:
NCT02662309
). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21â41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
datePublished:2019-11-04T00:00:00Z
dateModified:2023-03-21T00:00:00Z
pageStart:1706
pageEnd:1714
sameAs:https://doi.org/10.1038/s41591-019-0628-7
keywords:
Bladder cancer
Predictive markers
Biomedicine
general
Cancer Research
Metabolic Diseases
Infectious Diseases
Molecular Medicine
Neurosciences
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig3_HTML.png
isPartOf:
name:Nature Medicine
issn:
1546-170X
1078-8956
volumeNumber:25
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Thomas Powles
url:http://orcid.org/0000-0001-7760-4724
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Mark Kockx
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Alejo Rodriguez-Vida
affiliation:
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Ignacio Duran
affiliation:
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
type:Organization
type:Person
name:Simon J. Crabb
url:http://orcid.org/0000-0003-3521-9064
affiliation:
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
type:Organization
type:Person
name:Michiel S. Van Der Heijden
affiliation:
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
type:Organization
type:Person
name:Bernadett Szabados
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Albert Font Pous
affiliation:
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
type:Organization
type:Person
name:Gwenaelle Gravis
affiliation:
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Urbano Anido Herranz
url:http://orcid.org/0000-0003-0376-5642
affiliation:
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
type:Organization
type:Person
name:Andrew Protheroe
url:http://orcid.org/0000-0001-9413-0575
affiliation:
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
type:Organization
type:Person
name:Alain Ravaud
affiliation:
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
type:Organization
type:Person
name:Denis Maillet
affiliation:
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
type:Organization
type:Person
name:Maria Jose Mendez
url:http://orcid.org/0000-0002-7460-1859
affiliation:
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
type:Organization
type:Person
name:Cristina Suarez
affiliation:
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Mark Linch
affiliation:
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
type:Organization
type:Person
name:Aaron Prendergast
url:http://orcid.org/0000-0002-9668-6689
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Pieter-Jan van Dam
url:http://orcid.org/0000-0001-9074-8271
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Diana Stanoeva
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sofie Daelemans
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sanjeev Mariathasan
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Joy S. Tea
url:http://orcid.org/0000-0002-3395-149X
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Kelly Mousa
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Romain Banchereau
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Daniel Castellano
affiliation:
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Nature Medicine
issn:
1546-170X
1078-8956
volumeNumber:25
Organization:
name:Nature Publishing Group US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Thomas Powles
url:http://orcid.org/0000-0001-7760-4724
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
email:[email protected]
name:Mark Kockx
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:Alejo Rodriguez-Vida
affiliation:
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
type:Organization
name:Ignacio Duran
affiliation:
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
type:Organization
name:Simon J. Crabb
url:http://orcid.org/0000-0003-3521-9064
affiliation:
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
type:Organization
name:Michiel S. Van Der Heijden
affiliation:
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
type:Organization
name:Bernadett Szabados
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
name:Albert Font Pous
affiliation:
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
type:Organization
name:Gwenaelle Gravis
affiliation:
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
type:Organization
name:Urbano Anido Herranz
url:http://orcid.org/0000-0003-0376-5642
affiliation:
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
type:Organization
name:Andrew Protheroe
url:http://orcid.org/0000-0001-9413-0575
affiliation:
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
type:Organization
name:Alain Ravaud
affiliation:
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
type:Organization
name:Denis Maillet
affiliation:
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
type:Organization
name:Maria Jose Mendez
url:http://orcid.org/0000-0002-7460-1859
affiliation:
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
type:Organization
name:Cristina Suarez
affiliation:
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
type:Organization
name:Mark Linch
affiliation:
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
type:Organization
name:Aaron Prendergast
url:http://orcid.org/0000-0002-9668-6689
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
name:Pieter-Jan van Dam
url:http://orcid.org/0000-0001-9074-8271
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:Diana Stanoeva
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:Sofie Daelemans
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
type:Organization
name:Sanjeev Mariathasan
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
name:Joy S. Tea
url:http://orcid.org/0000-0002-3395-149X
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
name:Kelly Mousa
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
name:Romain Banchereau
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
name:Daniel Castellano
affiliation:
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
type:Organization
PostalAddress:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:HistogeneX N.V., Wilrijk, Belgium
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
name:Institut Paoli-Calmettes, Marseille, France
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
name:Department of Medical Oncology, University College London Hospital, London, UK
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:HistogeneX N.V., Wilrijk, Belgium
name:HistogeneX N.V., Wilrijk, Belgium
name:HistogeneX N.V., Wilrijk, Belgium
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
name:Genentech, San Francisco, USA
name:Genentech, San Francisco, USA
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:Genentech, San Francisco, USA
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
Social Networks {👍}(2)
External Links {🔗}(127)
- Find out how much https://orcid.org/0000-0001-7760-4724 earns monthly
- How much revenue does https://orcid.org/0000-0003-3521-9064 generate?
- Learn about the earnings of https://orcid.org/0000-0003-0376-5642
- Check the income stats for https://orcid.org/0000-0001-9413-0575
- How much money does https://orcid.org/0000-0002-7460-1859 generate?
- What's the income of https://orcid.org/0000-0002-9668-6689?
- How much cash flow does https://orcid.org/0000-0001-9074-8271 have monthly?
- What's the monthly income of https://orcid.org/0000-0002-3395-149X?
- How much does https://doi.org/10.1038/s41591-023-02312-9 pull in?
- How much profit is https://doi.org/10.1038/s41591-020-0923-3 making per month?
- Income figures for https://clinicaltrials.gov/ct2/show/NCT02662309?term=NCT02662309&rank=1
- https://link.springer.com/article/10.1038/s41591-019-0628-7?utm_source=nature&utm_medium=referral&utm_campaign=buyArticle income
- How much does https://doi.org/10.1016%2Fj.ctrv.2017.01.007 gross monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=A%20review%20on%20the%20evolution%20of%20PD-1%2FPD-L1%20immunotherapy%20for%20bladder%20cancer%3A%20the%20future%20is%20now&journal=Cancer%20Treat.%20Rev.&doi=10.1016%2Fj.ctrv.2017.01.007&volume=54&pages=58-67&publication_year=2017&author=Bellmunt%2CJ&author=Powles%2CT&author=Vogelzang%2CNJ pull in monthly?
- How profitable is https://doi.org/10.1016%2FS0140-6736%2817%2933297-X?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20versus%20chemotherapy%20in%20patients%20with%20platinum-treated%20locally%20advanced%20or%20metastatic%20urothelial%20carcinoma%20%28IMvigor211%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%203%20randomised%20controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2817%2933297-X&volume=391&pages=748-757&publication_year=2018&author=Powles%2CT
- How much does https://doi.org/10.1038%2Fnature25501 pull in monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=TGF-%CE%B2%20attenuates%20tumour%20response%20to%20PD-L1%20blockade%20by%20contributing%20to%20exclusion%20of%20T%20cells&journal=Nature&doi=10.1038%2Fnature25501&volume=554&pages=544-548&publication_year=2018&author=Mariathasan%2CS net monthly?
- Learn about the earnings of https://doi.org/10.1038%2Fs41591-018-0198-0
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20versus%20adjuvant%20ipilimumab%20plus%20nivolumab%20in%20macroscopic%20stage%20III%20melanoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-018-0198-0&volume=24&pages=1655-1661&publication_year=2018&author=Blank%2CCU?
- What are the earnings of https://doi.org/10.1200%2FJCO.18.01148?
- http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20as%20neoadjuvant%20therapy%20before%20radical%20cystectomy%20in%20patients%20with%20muscle-invasive%20urothelial%20bladder%20carcinoma%20%28PURE-01%29%3A%20an%20open-label%2C%20single-arm%2C%20phase%20II%20study&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.18.01148&volume=36&pages=3353-3360&publication_year=2018&author=Necchi%2CA's revenue stream
- What are the earnings of https://doi.org/10.1038%2Fs41591-018-0337-7?
- What's the income of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20anti-PD-1%20immunotherapy%20promotes%20a%20survival%20benefit%20with%20intratumoral%20and%20systemic%20immune%20responses%20in%20recurrent%20glioblastoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-018-0337-7&volume=25&pages=477-486&publication_year=2019&author=Cloughesy%2CTF?
- What's the income of https://doi.org/10.1038%2Fs41591-018-0197-1?
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20immune%20checkpoint%20blockade%20in%20high-risk%20resectable%20melanoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-018-0197-1&volume=24&pages=1649-1654&publication_year=2018&author=Amaria%2CRN
- What's https://doi.org/10.1016%2Fj.eururo.2014.01.009's gross income?
- Profit of http://scholar.google.com/scholar_lookup?&title=Trends%20in%20the%20use%20of%20perioperative%20chemotherapy%20for%20localized%20and%20locally%20advanced%20muscle-invasive%20bladder%20cancer%3A%20a%20sign%20of%20changing%20tides&journal=Eur.%20Urol.&doi=10.1016%2Fj.eururo.2014.01.009&volume=67&pages=165-170&publication_year=2015&author=Reardon%2CZD
- How much profit does https://doi.org/10.1200%2FJCO.2010.32.3139 make?
- How much does http://scholar.google.com/scholar_lookup?&title=International%20phase%20III%20trial%20assessing%20neoadjuvant%20cisplatin%2C%20methotrexate%2C%20and%20vinblastine%20chemotherapy%20for%20muscle-invasive%20bladder%20cancer%3A%20long-term%20results%20of%20the%20BA06%2030894%20trial&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2010.32.3139&volume=29&pages=2171-2177&publication_year=2011 rake in every month?
- What's the monthly money flow for https://doi.org/10.1158%2F1078-0432.CCR-15-1208?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Pathological%20T0%20following%20cisplatin-based%20neoadjuvant%20chemotherapy%20for%20muscle-invasive%20bladder%20cancer%3A%20a%20network%20meta-analysis&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-15-1208&volume=22&pages=1086-1094&publication_year=2016&author=Kim%2CHS&author=Jeong%2CCW&author=Kwak%2CC&author=Kim%2CHH&author=Ku%2CJH
- What's the total monthly financial gain of https://doi.org/10.1056%2FNEJMoa1716078?
- How much income is http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20blockade%20in%20resectable%20lung%20cancer&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1716078&volume=378&pages=1976-1986&publication_year=2018&author=Forde%2CPM earning monthly?
- Discover the revenue of https://doi.org/10.1038%2Fs41591-019-0357-y
- What's the income of http://scholar.google.com/scholar_lookup?&title=A%20single%20dose%20of%20neoadjuvant%20PD-1%20blockade%20predicts%20clinical%20outcomes%20in%20resectable%20melanoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-019-0357-y&volume=25&pages=454-461&publication_year=2019&author=Huang%2CAC?
- What's https://doi.org/10.1016%2FS0140-6736%2816%2900561-4's gross income?
- What's http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy%3A%20a%20single-arm%2C%20multicentre%2C%20phase%202%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2816%2900561-4&volume=387&pages=1909-1920&publication_year=2016&author=Rosenberg%2CJE's gross income?
- What's the total monthly financial gain of https://doi.org/10.1016%2Fj.cellimm.2007.07.004?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Granzyme%20B%20production%20distinguishes%20recently%20activated%20CD8%2B%20memory%20cells%20from%20resting%20memory%20cells&journal=Cell%20Immunol&doi=10.1016%2Fj.cellimm.2007.07.004&volume=247&pages=36-48&publication_year=2007&author=Nowacki%2CTM
- How much profit is https://doi.org/10.1200%2FJCO.2018.36.6_suppl.409 making per month?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20%28atezo%29%20vs.%20chemotherapy%20%28chemo%29%20in%20platinum-treated%20locally%20advanced%20or%20metastatic%20urothelial%20carcinoma%20%28mUC%29%3A%20immune%20biomarkers%2C%20tumor%20mutational%20burden%20%28TMB%29%2C%20and%20clinical%20outcomes%20from%20the%20phase%20III%20IMvigor211%20study&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2018.36.6_suppl.409&volume=36&pages=409-409&publication_year=2018&author=Powles%2CT have monthly?
- What's the income generated by https://doi.org/10.1200%2FJCO.2017.75.7740 each month?
- How much does http://scholar.google.com/scholar_lookup?&title=Alterations%20in%20DNA%20damage%20response%20and%20repair%20genes%20as%20potential%20marker%20of%20clinical%20benefit%20from%20PD-1%2FPD-L1%20blockade%20in%20advanced%20urothelial%20cancers&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2017.75.7740&volume=36&pages=1685-1694&publication_year=2018&author=Teo%2CMY make?
- https://doi.org/10.1038%2Fnm.2807 income
- How much income is http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20fibrosis%3A%20therapeutic%20translation%20for%20fibrotic%20disease&journal=Nat.%20Med.&doi=10.1038%2Fnm.2807&volume=18&pages=1028-1040&publication_year=2012&author=Wynn%2CTA&author=Ramalingam%2CTR earning monthly?
- How much does https://doi.org/10.1038%2Fonc.2016.353 generate monthly?
- http://scholar.google.com/scholar_lookup?&title=Cancer-associated%20fibroblast%20exosomes%20regulate%20survival%20and%20proliferation%20of%20pancreatic%20cancer%20cells&journal=Oncogene&doi=10.1038%2Fonc.2016.353&volume=36&pages=1770-1778&publication_year=2017&author=Richards%2CKE's financial summary
- https://doi.org/10.1158%2F1078-0432.CCR-12-0077-T's revenue stream
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=A%20molecular%20taxonomy%20for%20urothelial%20carcinoma&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-12-0077-T&volume=18&pages=3377-3386&publication_year=2012&author=Sjodahl%2CG?
- Check the income stats for https://doi.org/10.1016%2Fj.eururo.2018.09.003
- See how much http://scholar.google.com/scholar_lookup?&title=Intratumoral%20heterogeneity%20of%20bladder%20cancer%20by%20molecular%20subtypes%20and%20histologic%20variants&journal=Eur.%20Urol.&doi=10.1016%2Fj.eururo.2018.09.003&volume=75&pages=18-22&publication_year=2019&author=Warrick%2CJI makes per month
- How much does https://doi.org/10.1080%2F2162402X.2018.1488359 gross monthly?
- Earnings of http://scholar.google.com/scholar_lookup?&title=WEE1%20kinase%20inhibition%20reverses%20G2%2FM%20cell%20cycle%20checkpoint%20activation%20to%20sensitize%20cancer%20cells%20to%20immunotherapy&journal=Oncoimmunology&doi=10.1080%2F2162402X.2018.1488359&volume=7&publication_year=2018&author=Sun%2CL
- What's the profit of https://doi.org/10.1158%2F1078-0432.CCR-18-3334?
- How much does http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20I%20study%20of%20erdafitinib%20%28JNJ-42756493%29%2C%20oral%20pan-fibroblast%20growth%20factor%20receptor%20inhibitor%2C%20in%20patients%20with%20advanced%20or%20refractory%20solid%20tumors&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-18-3334&volume=25&pages=4888-4897&publication_year=2019&author=Bahleda%2CR rake in every month?
- How much does https://doi.org/10.1158%2F1078-0432.CCR-18-3147 rake in every month?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Mutational%20analysis%20of%20472%20urothelial%20carcinoma%20across%20grades%20and%20anatomic%20sites&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-18-3147&volume=25&pages=2458-2470&publication_year=2019&author=Nassar%2CAH generate?
- How much does https://doi.org/10.1056%2FNEJMoa1817323 generate monthly?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Erdafitinib%20in%20locally%20advanced%20or%20metastatic%20urothelial%20carcinoma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1817323&volume=381&pages=338-348&publication_year=2019&author=Loriot%2CY?
- Learn how profitable https://doi.org/10.1002%2Fsim.721 is on a monthly basis
- Earnings of http://scholar.google.com/scholar_lookup?&title=Sample%20size%20tables%20for%20exact%20single-stage%20phase%20II%20designs&journal=Stat.%20Med.&doi=10.1002%2Fsim.721&volume=20&pages=859-866&publication_year=2001&author=A%E2%80%99Hern%2CRP
- How much revenue does https://citation-needed.springer.com/v2/references/10.1038/s41591-019-0628-7?format=refman&flavour=references generate?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Thomas%20Powles's financial summary
- How much income is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Thomas%20Powles%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earning monthly?
- Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20Kockx
- What's the financial outcome of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20Kockx%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alejo%20Rodriguez-Vida generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alejo%20Rodriguez-Vida%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in monthly?
- What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ignacio%20Duran?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ignacio%20Duran%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in?
- Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Simon%20J.%20Crabb
- What is the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Simon%20J.%20Crabb%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michiel%20S.%20Van%20Der%20Heijden
- How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michiel%20S.%20Van%20Der%20Heijden%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- Learn how profitable https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bernadett%20Szabados is on a monthly basis
- What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bernadett%20Szabados%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
- What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Albert%20Font%20Pous each month?
- What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Albert%20Font%20Pous%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gwenaelle%20Gravis?
- What are the total earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gwenaelle%20Gravis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Urbano%20Anido%20Herranz's gross income?
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Urbano%20Anido%20Herranz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andrew%20Protheroe generate monthly?
- How much cash flow does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andrew%20Protheroe%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have monthly?
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alain%20Ravaud generate?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alain%20Ravaud%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Denis%20Maillet net monthly?
- What are the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Denis%20Maillet%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Maria%20Jose%20Mendez?
- Find out how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Maria%20Jose%20Mendez%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earns monthly
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cristina%20Suarez make?
- What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cristina%20Suarez%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20Linch
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20Linch%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Aaron%20Prendergast?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Aaron%20Prendergast%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate monthly?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Pieter-Jan%20van%20Dam pull in monthly?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Pieter-Jan%20van%20Dam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Diana%20Stanoeva gross monthly?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Diana%20Stanoeva%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
- What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sofie%20Daelemans?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sofie%20Daelemans%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
- What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sanjeev%20Mariathasan?
- How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sanjeev%20Mariathasan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Joy%20S.%20Tea?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Joy%20S.%20Tea%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kelly%20Mousa?
- How much cash flow does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kelly%20Mousa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have monthly?
- What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Romain%20Banchereau?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Romain%20Banchereau%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Daniel%20Castellano?
- How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Daniel%20Castellano%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
- Monthly income for https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_MOESM1_ESM.pdf
- How much does https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_MOESM2_ESM.pdf make?
- What's the income of https://s100.copyright.com/AppDispatchServlet?title=Clinical%20efficacy%20and%20biomarker%20analysis%20of%20neoadjuvant%20atezolizumab%20in%20operable%20urothelial%20carcinoma%20in%20the%20ABACUS%20trial&author=Thomas%20Powles%20et%20al&contentID=10.1038%2Fs41591-019-0628-7©right=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20America%2C%20Inc.&publication=1078-8956&publicationDate=2019-11-04&publisherName=SpringerNature&orderBeanReset=true?
- Profit of https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-019-0628-7
- How much income does https://citation-needed.springer.com/v2/references/10.1038/s41591-019-0628-7?format=refman&flavour=citation have?
- What is the earnings of https://doi.org/10.1038/s41698-025-00846-4?
- https://doi.org/10.1038/s41571-024-00984-x income
- What's the financial outcome of https://doi.org/10.1038/s43018-025-00990-7?
- How much does https://doi.org/10.1038/s41467-024-55665-1 earn?
- How much revenue does https://doi.org/10.1038/s41598-025-99889-7 generate?
- How much money does https://www.protocols.io/ generate?
- How much revenue does https://www.natureindex.com/ produce monthly?
- How much revenue does http://www.naturechina.com produce monthly?
- Monthly income for https://www.natureasia.com/ja-jp
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref